SLIDE 1 Academy Health Annual Research Meeting, Boston 2016
Diagnostic Research Methods: Brief Overview plus a Deeper Dive into Big Data for Diagnostic Error
David E. Newman-Toker, MD PhD
Associate Professor of Neurology Johns Hopkins University School of Medicine Johns Hopkins Bloomberg School of Public Health Johns Hopkins Armstrong Institute for Patient Safety & Quality
SLIDE 2 DISCLOSURES
1.
Grant support
NIH U01 DC013778-01A1 (NIDCD), 5U01NS080824, (NINDS), U24TR001609-01 (NCATS), AHRQ (pending)
Siemens/SIDM, Brainscope, Kaiser Permanente
2.
Research VOG devices loaned by
GN Otometrics
Autronics-Interacoustics
3.
Founding Board Member SIDM (unpaid)
4.
‘Diagnosis’ career focus (academic COI)
Investigational Use – Device
SLIDE 3 OBJECTIVES
1) Discuss the link between different diagnostic research contexts and choice of research methods 2) List at least one method for each diagnostic safety measurement objective (burden, causes, solutions) 3) Describe analytic methods and techniques to enhance ‘big data for diagnostic error’ research
Newman-Toker
SLIDE 4 OUTLINE
1) Conceptual Model Defining Research Space 2) Linking Conceptual Model to Research Methods 3) Deep(er) Dive into Big Data for Diagnostic Error 4) Final Thoughts & Take Home Messages 5) Questions/Panel Discussion
Newman-Toker
SLIDE 5
CONCEPTUAL MODEL
FOR RESEARCH SPACE
SLIDE 6 IOM Definition of Diagnostic Error
DIAGNOSTIC ERROR is the failure to…
(a) establish an accurate and timely explanation
- f the patient’s health problem(s) or
(b) communicate that explanation to the patient
SLIDE 7 Diagnostic Process Failure Diagnosis Label Failure Preventable Diagnostic Error “No Fault” Misdiagnosis “Near Miss” Process Failure
Newman-T
Opportunity for… Quality Assurance
Safety
SLIDE 8 Diagnostic Process Failure
N O H A R M
Suboptimal Diagnostic Process Diagnosis Label Failure Optimal Diagnostic Process UNDIAGNOSED & UNDIAGNOSABLE Standard yet Suboptimal Care Preventable Diagnostic Error “NEAR MISS” PROCESS PROBLEM* HARM FROM OVERTESTING & OVERDIAGNOSIS*
H A R M
Opportunity for… Quality Improvement
Dissemination
Opportunity for… Quality Assurance
Safety
Opportunity for… New Science
Discovery
Newman-T
SLIDE 9 Diagnostic Process Failure
N O H A R M
Suboptimal Diagnostic Process Diagnosis Label Failure Optimal Diagnostic Process UNDIAGNOSED & UNDIAGNOSABLE Standard yet Suboptimal Care Preventable Diagnostic Error “NEAR MISS” PROCESS PROBLEM* HARM FROM OVERTESTING & OVERDIAGNOSIS*
H A R M
Opportunity for… Quality Improvement
Dissemination
Opportunity for… Quality Assurance
Safety
Opportunity for… New Science
Discovery
Newman-T
SLIDE 10
LINKING MODEL TO RESEARCH METHODS
SLIDE 11 LINKING MODELS & METHODS DISCOVERY RESEARCH IN DIAGNOSIS
Newman-Toker
Validation Cross-Sectional E2E, Cluster RCT Works? Accurate? Δ Tests? Δ Treatment? Δ Outcomes? Phase III RCT Phase II RCT
Opportunity for… New Science
Discovery
SLIDE 12 Pronovost, BMJ 2008
TRIP Conceptual Model (v2)
Translating Research Into Practice Opportunity for… Quality Improvement
Dissemination Implementation Science Outcome Methods (e.g., Quasi-Experimental, Stepped Wedge)
SLIDE 13 Newman-Toker
Burden Cause
Methods (‘Meta’)
Solution
LINKING MODELS & METHODS SAFETY DOMAINS
Opportunity for… Quality Assurance
Safety Simulations, Experiments Qualitative (RCA, process) Case-Control, Cohort Pre-Post, Stepped Wedge Diagnostic Strategy RCT Meta-Analysis, Modeling Patient, Provider Surveys Concordance, Spectrum (OverDx) Surveillance for Unplanned Events
SLIDE 14
DEEP(ER) DIVE INTO BIG DATA FOR DX ERROR
SLIDE 15 Newman-Toker
BIG DATA FOR DX ERROR CASE STUDY: MISSED STROKE IN DIZZINESS
A 30 year-old woman presents with new vertigo and vomiting to the ED. Woke with symptoms this morning and still has them 12 hours later. Associated with nausea, vomiting, head motion intolerance, gait
- unsteadiness. No other neurologic symptoms.
Does the patient have a stroke? ED physician orders a CT scan of the brain. When it returns with a normal result, the patient is discharged with medication (meclizine) for “labyrinthitis” and told to follow up with their primary care provider. The patient returns 48 hours later herniating from a large posterior fossa stroke, and ends up disabled in a nursing home.
SLIDE 16 LARGE CEREBELLAR INFARCTION
medial PICA-territory stroke, dimensions 3.0 x 5.0 x 4.4 cm
SLIDE 17 Newman-Toker
BIG DATA FOR DX ERROR CASE STUDY: MISSED STROKE IN DIZZINESS
We know this happens, but… How often? and… How can we monitor it operationally for performance feedback and to measure impact of solutions?
SLIDE 18 BIG DATA FOR DX ERROR
MISSED STROKE IN “BENIGN” DIZZINESS
Look Back Approach: Stroke patients more likely to have been discharged from ED with “benign” dizziness prior ~14 days (N = ~180,000 strokes) Look Forward Approach: ‘Benign’ dizziness sent home from ED more likely to return with a stroke within ~30 days, but not heart attack (N = ~30,000 ED dizzy discharges)
SLIDE 19 Look Back (Outcome to Symptoms)
Stroke
- Dizziness
- Headache
- Numbness
Myocardial Infarction
- Chest pain
- Back pain
- Dyspnea
Pulmonary Embolus
- Dyspnea
- Chest pain
- Back pain
SLIDE 20 Look Forward (Symptoms to Outcome)
Dizziness Vertigo
infarction
Headache
hemorrhage
Back Pain
infarction
- Aortic dissection
- Spinal cord
compression
SLIDE 21
BIG DATA FOR DX ERROR
PEARL #1 – LUMP FOR LOOK BACK
PROBLEM: Variable Granularity Administrative Data SOLUTION: ‘Lump’ Sensibly Using HCUP-CCS
SLIDE 22
BIG DATA FOR DX ERROR
PEARL #2 – USE O/E, TEMPORAL ANALYSIS
PROBLEM: Risk of Spurious Association SOLUTION: Use O/E and temporal profile
SLIDE 23
BIG DATA FOR DX ERROR
PEARL #3 – USE CONTROL GROUPS
PROBLEM: Risk of Non-Specific Association SOLUTION: Use Clinical Comparison Groups
SLIDE 24
FINALTHOUGHTS & TAKE HOME MESSAGES
SLIDE 25
Diagnostics Development Pipeline
SLIDE 26
Gaps in the Diagnostic Research Translational Continuum
SLIDE 27 TAKE HOME POINTS
1) Match methods to research context (discovery, dissemination, or safety) 2) Consider your measurement objectives in the safety space (burdens, causes, solutions) 3) With ‘big data for diagnostic error’ combine ‘look back’ with ‘look forward’ and use analytic pearls (lump, O/E-time, control)
Newman-Toker
SLIDE 28
QUESTIONS & PANEL DISCUSSION
SLIDE 29
DIAGNOSTIC STRATEGY RCT
SOLUTIONS THROUGH INNOVATION
Portable Video-oculography: The “Eye ECG” AVERT Trial (NIH-sponsored $5.5M Phase II RCT)
SLIDE 30